Rapport Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Rapport Therapeutics, Inc. (RAPP) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 188.62 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-05
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 71.45K shares.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 117.17K shares, a 38.45% decline year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 41.46K shares, a 41.71% increase year-over-year.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 231.82K shares, a 340.66% increase from fiscal 2024.
- Rapport Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 52.61K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 71.45K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 188.62K shares 10-Q · filed 2026-08-05 | 230.08K shares derived: sum of 3 quarters · filed 2026-08-05 | 230.08K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 117.17K shares 10-Q · filed 2026-05-07 | 158.63K shares derived: sum of 2 quarters · filed 2026-05-07 | 158.63K shares derived: sum of 3 quarters · filed 2026-05-07 | 158.63K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 41.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 41.46K shares derived: sum of 2 quarters · filed 2026-03-10 | 41.46K shares derived: sum of 3 quarters · filed 2026-03-10 | 231.82K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-06 | 190.36K shares 10-Q · filed 2025-11-06 | 219.62K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 190.36K shares 10-Q · filed 2025-08-07 | 219.62K shares derived: sum of 3 quarters · filed 2025-08-07 | |
| 2025-03-31 | 190.36K shares 10-Q · filed 2025-05-08 | 219.62K shares derived: sum of 2 quarters · filed 2025-05-08 | ||
| 2024-12-31 | 29.26K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | 52.61K shares 10-K · filed 2025-03-11 | ||
| 2024-09-30 | 23.35K shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |